Breaking News

Facebook Quarterly Profit of 42 Cents a Share Exceeds Analysts’ Estimate
Tweet TWEET

ArQule to Present at Jefferies Global Healthcare Conference

  ArQule to Present at Jefferies Global Healthcare Conference  Jefferies 2014 Global Healthcare Conference  Business Wire  WOBURN, Mass. -- May 29, 2014  ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 10:30 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://investors.arqule.com/events.cfm.  About ArQule  ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent and selective against their targets.  Contact:  ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com